The U.S. International Trade Commission launched an investigation into Chinese state support and pricing practices in the biotech sector, probing whether government intervention and subsidies have distorted markets and disadvantaged U.S. firms. The inquiry could lay the groundwork for trade remedies, including tariffs or restrictions, depending on findings. BioCentury reported the probe will analyze Chinese industrial policy, preferential financing, and transaction behavior to assess competitive harm. The review arrives as Western investors and policymakers scrutinize supply-chain exposures and national-security dimensions of advanced life-science capacity. Industry participants said the investigation could reshape cross-border deals and joint ventures, and warned it may prompt more rigorous scrutiny of inbound Chinese investments into biomanufacturing and platform technologies.